Vermont legislation · 2025-2026 Session
Vermont S154: An act relating to health insurance coverage for biomarker testing
Status: Passed one chamber, March 26, 2026
What the bill says
An act relating to health insurance coverage for biomarker testing It is hereby enacted by the General Assembly of the State of Vermont.
From the engrossed text, March 24, 2026:
An act relating to health insurance coverage for biomarker testing It is hereby enacted by the General Assembly of the State of Vermont: Sec. 1. 8 V.S.A. § 4088n is added to read: § 4088n. COVERAGE FOR BIOMARKER TESTING (a) As used in this section: (1) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include gene mutations, characteristics of genes, and protein expression. BILLAS INTRODUCED AND PASSED BY SENATE S.154 2025 Page 2 of (2) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes single-analyte tests, multiplexpanel tests, protein expression analysis, and whole exome, whole genome, and whole transcriptome sequencing. (3) "Consensus statements" means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy. These statements are aimed at specific clinical circumstances and the statements are based on the best available evidence for the purpose of optimizing the outcomes of clinical care. (4) "Health insurance plan" means any health insurance policy or health benefit plan offered by a health insurer, …
Sponsors
- Martine Gulick (D, Chittenden-Central District) · primary sponsor
- Randolph Brock (R, Franklin District) · primary sponsor
- Joseph Major (D, Windsor District)
- Tanya Vyhovsky (D, Chittenden-Central District)
Latest actions
- : Read first time and referred to the Committee on [Health Care]
- : Read 3rd time & passed
- : New Business/Third Reading
- : 3rd reading ordered
- : Recommendation of amendment by Committee on [Health and Welfare] agreed to
- : Reported favorably by Senator [Lyons] for Committee on [Appropriations]
- : Read 2nd time, reported favorably with recommendation of amendment by Senator [Cummings] for Committee on [Health and Welfare]
- : Favorable report by Committee on [Appropriations]
- : Favorable report with recommendation of amendment by Committee on [Health and Welfare]
- : Second Reading
Common questions
- What is S154?
- S154 is a bill in the Vermont Legislature (2025-2026 Session): An act relating to health insurance coverage for biomarker testing.
- What does S154 do?
- In its own words: An act relating to health insurance coverage for biomarker testing It is hereby enacted by the General Assembly of the State of Vermont.
- What is the status of S154?
- Passed one chamber as of March 26, 2026. Latest action: Read first time and referred to the Committee on [Health Care] (March 26, 2026).
- Who sponsored S154?
- Martine Gulick (D, Chittenden-Central District), with 3 co-sponsors.
- Where is the official record for S154?
- On the Vermont Legislature website: https://legislature.vermont.gov/bill/status/2026/S.154
Source: official Vermont record. Tracked by Delilah, AI for legislation across all 50 states and Congress.